Company intelligence / Profile preview

Re-Vana Therapeutics Ltd

Belfast, Northern Ireland, United Kingdomrevanawine.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Re-Vana has demonstrated that its proprietary platforms can achieve six months or greater sustained delivery of anti‑VEGF biologics at therapeutically relevant levels with high drug loading and favorable degradation profiles. Key nonclinical studies have shown promising safety, tolerability, and efficacy results. Clinical trials have not yet been reported.

Therapeutic areas: Ophthalmology
Modalities: Biologics (e.g., anti-VEGFs, biosimilars)Small molecules (e.g., peptides, prostaglandins, TKIs)
Industry: Biotech

Drug pipeline

1 asset

AVD-104

Phase 2/3

Indications: Geographic atrophy, Age-related macular degeneration

Partnerships

Several global pharmaceutical companies are collaborating on preformulation and preclinical feasibility studies. Names undisclosed.

Beyond the preview

Go deeper on Re-Vana Therapeutics Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Re-Vana Therapeutics Ltd.

Explore the full profile